Ahead of the Curve

ABOUT oRNA

Orna Therapeutics is leaving linear thinking behind to create fully engineered circular RNA (oRNA) therapeutics – an entirely new class of RNA medicines that can realize the full potential of RNA and which is poised to change the way we treat disease.

ORNA’S APPROACH

RNA has recently ascended as a therapeutic class with vast potential. Existing mRNA technologies, however, face numerous and ongoing challenges to production, delivery, and performance. Circular RNA, by its very nature, has the potential to address these challenges, but the technology to create and engineer these molecules efficiently in a laboratory setting remained undeveloped. Orna now has this technology – building on nature’s ingenuity with our sophisticated molecular innovations to advance a system for protein expression, RNA production, and superior delivery compared to conventional long RNA approaches. We have married these capabilities with exciting delivery solutions to create a simple, powerful platform: the next breakthrough in RNA therapeutics.

Our Team

Creating a new class of therapeutics requires thinking outside the lines. Comprised of a team of skilled scientists, molecular engineers, and industry veterans in addition to a world class Board, we are well-suited for the challenge of bringing the promise of oRNA to patients.

Thomas M. Barnes, PhD
Chief Executive Officer
John J. McCabe, CPA
Chief Financial Officer
Brian Goodman, PhD
Interim VP, Business Development
Daniel Anderson, PhD
Professor, Massachusetts Institute of Technology
Sakae Asanuma, CFA
President, Taiho Ventures
Thomas M. Barnes, PhD
CEO, Orna Therapeutics
Thomas Ebeling
Advisor, MPM Capital

NEWS & MEDIA

MPM raises $850M for second Impact Fund as exits pile up from first

October 8, 2021 – With returns from early investments turning into grants for future research, MPM Capital has raised $850 million for its second Oncology Impact Fund, easily surpassing the size of its prior vehicle. Read More >

Biotech2050 Podcast

October 6, 2021 – Ep. 74 – Thomas Barnes, CEO | Orna Therapeutics Read More >

The Next RNA Breakthrough? Maybe Bending Strands Into Circles

October 1, 2021 – Investors flock to biotech startup Orna Therapeutics on the promise of low-cost treatment. Read More >
MPM raises $850M for second Impact Fund as exits pile up from first

October 8, 2021 – With returns from early investments turning into grants for future research, MPM Capital has raised $850 million for its second Oncology Impact Fund, easily surpassing the size of its prior vehicle.

Biotech2050 Podcast

October 6, 2021 – Ep. 74 – Thomas Barnes, CEO | Orna Therapeutics

The Next RNA Breakthrough? Maybe Bending Strands Into Circles

October 1, 2021 – Investors flock to biotech startup Orna Therapeutics on the promise of low-cost treatment.